11:10 AM ET 3/31/10 | BusinessWire
RELATED QUOTES
11:40 AM ET 3/31/10
Symbol Last % Chg
PGCX
0.02 -30.00%
Real time quote.
PanGenex Corporation (Pink Sheets: PGCX) ("PanGenex" or "the Company") a global manufacturer and distributor of nutraceutical and dietary supplement products, today released a statement in response to the many inquiries about Omega-3 and Lipideme.
Dr. Ronald Caputo, a PanGenex Board Member and one of America's leading Interventional Cardiologists, stated, "The benefits of Omega-3 fatty acids have been well established through multiple extensive clinical studies. They have been demonstrated to lower the risk of sudden cardiac death and improve blood lipid profiles. Omega-3 fatty acids are also safe and well tolerated without serious side effects. As such, they are well accepted by both the medical community and the general public. What is not generally appreciated is that not all Omega-3 supplements provide equivalent benefit. There are major differences between products in regard to purity and formulation.
There are several unique features of Lipideme that make it superior to other Omega-3 products. Firstly, it provides an extremely high level of pure and well balanced Omega-3 fatty acids, far surpassing any other commercially available "fish oil" supplement of which I am aware. This is incredibly important in order to avoid the unnecessary and detrimental heavy metals and non-Omega-3 fats found in other products. Secondly, this proprietary formulation also incorporates the other well established natural lipid lowering agents phytosterols and tocotrienols - the natural "statins". Thirdly, the inclusion of Co-enzyme Q adds an important anti-oxidant component to the compound.
As a high volume Interventional Cardiologist I am well acquainted with the results of untreated lipid abnormalities. I literally see blockages in coronary arteries every day. Lipideme provides an excellent option in the battle against coronary artery disease and I have seen significant clinical benefit in many patients from its use." Dr. Caputo concluded.
About PanGenex Corporation
PanGenex Corporation pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels to the FDA without incidence. PanGenex products are sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil and Australia, in fine retail establishments and on the Internet including: www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.
This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
SOURCE: PanGenex Corporation
PanGenex Corporation
Mindy Rippeto, 813-623-5268
investor@pangenex.com
News 
Market Data 
Discover 
